Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12303484-B2
Publication Date
2025-05-20
Expiration Date
Abstract
Disclosed herein is a method of treating patients with NSCLC subtypes of cancer by reducing tumor burden, comprising administering at least one dose of purified Ruthenium (III) Pyrazole complexes to patients suffering from NSCLC, wherein said dose is therapeutically sufficient. In one or more embodiments, the Ruthenium III Pyrazole is RuCl3(DMSO)(dmPyz)2.
Core Innovation
The disclosed subject matter concerns a method of treating a cancer patient by administering at least one dose of purified neutral ruthenium(III) pyrazole complexes, with emphasis on [RuCl3(dimethylsulfoxide)(3,5-dimethylpyrazole)2]. The target patient is described as having a non-small cell lung cancer subtype, and the dosing is therapeutically sufficient. The disclosure evaluates the activity of ruthenium(III) pyrazole complexes in lung cancer models.
The document provides background and rationale for ruthenium(III)-pyrazole agents and characterizes [RuCl3(dimethylsulfoxide)(3,5-dimethylpyrazole)2] by structural and bond metrics. It reports an X-ray crystal structure with monoclinic space groups Cc and P21/n, and discusses bond lengths for Ru-Cl, Ru-S, and Ru-N. It also lists alternative ruthenium(III) pyrazole complexes including RuCl3(DMSO-S)(pyz)2, RuCl3(DMSO-S)(DMSO-O)(pyz), RuCl3(bpy)(dmPyz)2, and mer-[RuCl3(DMSO)(dmpyz)2].
The disclosure includes in vitro efficacy data for NSCLC cell lines NCI-H522 and NCI-H23. A screening table indicates inhibition of NSCLC on the order of 97% at 10 μM, and dose-response results using MTT assay readouts are reported with ED50 values at 24/48/72 hours for both NCI-H522 and NCI-H23. The disclosure further discusses prior knowledge of Ru-pyrazole activity in breast cancer cells (MCF7) while asserting lack of expectation or teaching for NSCLC subtype activity.
Claims Coverage
The partial content provides one independent claim and two dependent refinements. Across these, the core claim structure contains an inventive feature centered on administering a specified ruthenium(III) pyrazole complex to treat a non-small cell lung cancer subtype.
Treating non-small cell lung cancer subtype using [RuCl3(dimethylsulfoxide)(3,5-dimethylpyrazole)2] dosing
A method of treating a cancer patient comprising administering at least one dose of [RuCl3(dimethylsulfoxide)(3,5-dimethylpyrazole)2] to the cancer patient, wherein the cancer patient has a non-small cell lung cancer subtype.
Adenocarcinoma non-small cell lung cancer subtype
The method of the prior feature where the non-small cell lung cancer subtype is adenocarcinoma.
Administered dose constrained to 0.1–10 μM of the ruthenium complex
The method of the prior feature performed with at least one dose containing between 0.1 and 10 μM of [RuCl3(dimethylsulfoxide)(3,5-dimethylpyrazole)2].
The claim coverage is directed to treating non-small cell lung cancer subtypes by administering [RuCl3(dimethylsulfoxide)(3,5-dimethylpyrazole)2], with further refinements specifying adenocarcinoma and constraining the administered dose to 0.1–10 μM.
Stated Advantages
Documented Applications
In vitro evaluation of purified neutral ruthenium(III) pyrazole complexes against NSCLC cell lines, including NCI-H522 and NCI-H23, using MTT assay readouts and ED50 calculations, including inhibition of NSCLC at 10 μM.
Interested in licensing this patent?